Jaguar to receive $5M monthly license fee payments along with a quarterly purchase of its common stock by SynWorld priced at $5M & an additional monthly service fee of ~$5M in unregistered Jaguar stock during the initial 2yrs. term of the agreement. SynWorld is responsible to obtain regulatory approval and commercialize the product following approval in China
Under the terms of the agreement, Jaguar will receive 60% of any profits from sales of Canalevia whereas, the profit-sharing will become 80% if Jaguar reimburses SynWorld for the expenses of obtaining regulatory approval in China
Canalevia (oral) is a plant-based extraction & purification of red bark sap used to treat CID in dogs. Canalevia has been approved by the US FDA in Dec’21 for the same indication
Ref: Accesswire | Image: Jaguar Health
